Moderna to scoop up genomics company for $85M

Moderna is set to acquire OriCiro for $85 million.

OriCiro Genomics K.K. is a company that specializes in cell-free DNA synthesis and amplification technologies, according to a Jan. 4 Moderna news release.

"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing," Stéphane Bancel, CEO of Moderna, said in the release. "OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars